The company is generating meaningful sales while burning through cash
Moderna enters 2026 carrying a paradox familiar to ambitious science: the company generates nearly two billion dollars in revenue while losing nearly three billion, a gap that reflects not failure of execution but the immense cost of becoming something larger than what it already is. The biotechnology firm, still transitioning beyond the pandemic franchise that made it famous, now holds a pipeline of 26 clinical programs spanning infectious disease and oncology — a portfolio built on borrowed time and borrowed capital. Whether the market's faith in that future, priced at more than eleven times the model's calculated fair value, will prove visionary or premature is the question that defines Moderna's present moment.
- A $2.8 billion net loss against $1.9 billion in revenue is not a stumble — it is a structural condition that has compounded at over 57% annually for five years, and shows no sign of reversing soon.
- Quarterly revenue swinging between $108 million and $1.9 billion exposes how dangerously dependent the business remains on COVID vaccine cycles, even as the company insists it is diversifying.
- Eighteen Phase II and six Phase III programs represent a genuine scientific bet on the future, but a pipeline is a promise, and promises do not close a nearly $3 billion annual cash gap.
- At $45.37 per share against a discounted cash flow fair value of $3.83, the market is not pricing in Moderna's present — it is pricing in a version of Moderna that does not yet exist.
- The company is caught between two legitimate truths: the losses are real and accelerating, and the growth thesis is real and expanding — and investors must decide which truth arrives first.
Moderna opened 2026 with results that crystallize the central tension of its investment story: $1.9 billion in trailing revenue alongside a $2.8 billion net loss, translating to a basic loss of $7.25 per share. This is not an isolated quarter — it is the continuation of a five-year pattern in which annual losses have compounded at 57.1 percent. Individual quarters have been punishing, including a $971 million loss in Q1 2025 and an $826 million loss in Q4. The one profitable quarter in recent memory, Q3 2024, stands as a solitary exception in an otherwise unbroken stretch of red ink.
The volatility in revenue tells its own story. Quarterly figures have ranged from $108 million to $1.9 billion — not because a diversified portfolio is maturing unevenly, but because the business remains heavily concentrated in COVID vaccine demand, which is seasonal, unpredictable, and structurally declining. The lumpiness is a warning about how much of the optimistic narrative is still theoretical.
The optimism, however, is not without foundation. Moderna now has 18 programs in Phase II and 6 in Phase III, extending well into oncology and infectious disease — markets far larger and more durable than the pandemic window that launched the company. Analysts project 28.6 percent annual revenue growth, a rate that, if realized, could eventually close the gap between ambition and arithmetic.
The valuation, though, strains credulity on current fundamentals. At $45.37 per share, Moderna trades at 9.3 times sales against a peer average of 5.4 times. More starkly, discounted cash flow analysis places fair value at $3.83 — a figure so distant from the market price that it implies investors are not evaluating the company as it is, but as it might become under near-perfect conditions. The question Moderna's next chapters must answer is whether that faith is prescience or projection.
Moderna opened 2026 with financial results that laid bare a tension at the heart of the company's investment thesis: substantial revenue paired with staggering losses. The biotechnology firm reported a net loss of $2.8 billion on trailing 12-month revenue of $1.9 billion, translating to a basic loss of $7.25 per share. This is not an anomaly. Over the past year, quarterly revenue has swung wildly between $108 million and $1.9 billion, while earnings per share have ranged from a rare $0.03 profit in the third quarter of 2024 to losses exceeding $2.50 in multiple quarters throughout 2025. The pattern is consistent enough to be unsettling: the company is generating meaningful sales while burning through cash at a rate that keeps investors and analysts locked in debate about whether the underlying business model can ever reach profitability.
For those tracking Moderna's losses over a longer horizon, the numbers tell a story of deterioration. Annual losses have grown at a compound rate of 57.1 percent over the past five years, with the most recent $2.8 billion loss fitting squarely into that troubling trajectory. Individual quarters have been brutal—a $971 million loss in the first quarter of 2025, followed by an $826 million loss in the fourth quarter. Even in the company's better quarters, such as the third quarter of 2025 when revenue hit $1 billion, the bottom line remained deeply negative at a $200 million loss. The sole profitable quarter in recent memory was Q3 2024, a solitary bright spot in an otherwise relentless march of red ink.
Yet the bulls have a counterargument, and it hinges on what Moderna is building rather than what it is currently earning. The company's pipeline has expanded well beyond its original COVID franchise, now encompassing 18 programs in Phase II clinical trials, 6 in Phase III, and 2 approved products as of the end of 2025. These candidates span infectious disease and oncology—therapeutic areas far larger and more durable than the pandemic market that made Moderna's early fortune. Analysts project revenue growth of 28.6 percent annually, a rate well above market averages, suggesting that if the pipeline delivers, the company could eventually grow into its losses. The diversification narrative is real: Moderna is no longer a one-product story.
But the revenue numbers themselves complicate that optimistic framing. The $108 million quarter in early 2025 and the $1.9 billion quarter in late 2024 are not the result of a portfolio spreading risk evenly across multiple blockbuster drugs. They reflect concentration and lumpiness—the business is still heavily dependent on how much COVID vaccine Moderna can sell in any given period, and that demand is volatile. A pipeline full of Phase II and Phase III programs is a promise, not a present reality. The gap between what the company is earning now and what it might earn if those programs succeed remains vast.
The valuation picture adds another layer of complexity. At $45.37 per share, Moderna trades at 9.3 times sales, a premium to its direct biotech peers, which average 5.4 times sales. Within the broader biotech industry, which trades at 11 times sales on average, Moderna sits in the middle—not the most expensive, but not cheap. The real disconnect emerges when analysts run discounted cash flow models. The DCF fair value they calculate is $3.83 per share, a figure that sits in a different universe from the current market price. That gap suggests the market is pricing in not just the pipeline's success, but a degree of success that the company's recent cash burn does not yet support.
What emerges from these numbers is a classic biotech dilemma: a company with genuine scientific assets and a credible growth strategy, but one that is currently unprofitable at a scale that raises questions about whether the market is pricing in too much optimism too soon. The losses are real and accelerating. The pipeline is real and expanding. The valuation premium is real and difficult to justify on current fundamentals. For investors, the question is whether Moderna's diversified pipeline and projected growth rate can bridge the chasm between a $2.8 billion annual loss and a stock price that assumes they will. The company's next chapters will determine whether that bet was prescient or reckless.
Citas Notables
Losses have grown at 57.1% per year over the past five years, and the trailing 12 month loss of $2.8 billion fits that concern.— Analysis of Moderna's financial trajectory
The DCF fair value figure of $3.83 is far below $45.37, which means the trailing period modelled cash flows do not on their own bridge the gap to the market price.— Valuation analysis
La Conversación del Hearth Otra perspectiva de la historia
Why does a company with nearly $2 billion in annual revenue still lose $2.8 billion?
Because the revenue is concentrated and volatile—mostly from COVID vaccines—while the company is spending heavily on research, development, and manufacturing for a pipeline that hasn't yet generated sales. It's investing for the future while the present is shrinking.
So the losses are intentional? A choice?
Partly. Biotech companies often operate at a loss while building pipelines. But Moderna's losses are accelerating—up 57 percent annually over five years—which suggests the company is either spending faster than revenue is growing, or revenue itself is declining faster than expected.
The pipeline sounds promising. Eighteen Phase II programs, six in Phase III. Doesn't that justify the stock price?
It justifies optimism, but not necessarily the current valuation. A DCF model—which tries to value the company based on projected future cash flows—suggests fair value around $3.83 per share. The stock trades at $45.37. That gap is enormous, and it assumes the pipeline will not just succeed, but succeed spectacularly.
What would need to happen for the bears to be right?
If the pipeline stumbles. If revenue from COVID continues to decline faster than new products can replace it. If the company can't reach profitability before cash runs out. The losses are already heavy; if they continue accelerating, the math becomes unsustainable.
And for the bulls?
Several of the Phase III programs need to succeed and reach the market. Revenue growth needs to hit that 28.6 percent target. And the company needs to improve margins—to do more with less spending. It's possible, but it requires execution on multiple fronts simultaneously.
So this is a bet on the pipeline.
Entirely. The current business is losing money. Everything hinges on whether those 24 programs in Phase II and Phase III can become approved drugs that generate enough revenue to turn the company profitable. That's not a certainty.